Shanklin J R, Johnson C P, Proakis A G, Barrett R J
Department of Chemical Research, A. H. Robins Company, Richmond, Virginia 23261-6609.
J Med Chem. 1991 Oct;34(10):3011-22. doi: 10.1021/jm00114a009.
A series of 4-(diarylmethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds were synthesized as calcium-channel blockers and antihypertensive agents. Compounds were evaluated for calcium-channel-blocking activity by determining their ability to antagonize calcium-induced contractions of isolated rabbit aortic strips. The most potent compounds were those with fluoro substituents in the 3- and/or 4-positions of both rings of the diphenylmethyl group. Bis(4-fluorophenyl)acetonitrile analogue 79 was similar in potency to bis(4-fluorophenyl)methyl compound 1. The methylene analogue of 1 (78) and derivatives of 1 that contained a hydroxyl (76), carbamoyl (80), amino (81), or acetamido (82) substituent on the methyl group were less potent. In most cases, substituents on the phenoxy ring, changes in the distance between the aryloxy group and the piperidine nitrogen, and the substitution of S, N(CH3), or CH2 for the oxygen atom of the aryloxy group had only a small to moderate effect on the potency. The best compounds in this series were more potent than verapamil, diltiazem, flunarizine, and lidoflazine, but were less potent than nifedipine. Compounds were evaluated for antihypertensive activity in spontaneously hypertensive rats (SHR) at an oral dose of 30 mg/kg. Of the 55 compounds tested, only nine produced a statistically significant (p less than 0.05) reduction in blood pressure greater than 20%; all of these compounds had fluoro substituents in both rings of the diphenylmethyl group. One of the most active compounds in the SHR at 30 mg/kg was 1-[4-[3-[4-[bis(3,4-difluorophenyl)methyl]-1- piperidinyl]propoxy]-3-methoxyphenyl]ethanone (63), which produced a 35% reduction in blood pressure and was similar in activity to nifedipine. At lower doses, however, 4-[bis(4-fluorophenyl)methyl]-1-[3-(4-chlorophenoxy)propyl]piperidine (93) was one of the most effective antihypertensive agents, producing reductions in blood pressure of 17 and 11% at oral doses of 10 and 3 mg/kg, respectively; 63 was inactive at 10 mg/kg.
合成了一系列4-(二芳基甲基)-1-[3-(芳氧基)丙基]哌啶及其结构相关的化合物作为钙通道阻滞剂和抗高血压药。通过测定它们拮抗钙诱导的离体兔主动脉条收缩的能力来评估化合物的钙通道阻滞活性。最有效的化合物是那些在二苯甲基两个环的3位和/或4位带有氟取代基的化合物。双(4-氟苯基)乙腈类似物79的效力与双(4-氟苯基)甲基化合物1相似。1的亚甲基类似物(78)以及在甲基上含有羟基(76)、氨基甲酰基(80)、氨基(81)或乙酰氨基(82)取代基的1的衍生物效力较低。在大多数情况下,苯氧基环上的取代基、芳氧基与哌啶氮之间距离的改变以及用硫、N(CH3)或CH2取代芳氧基的氧原子对效力只有较小到中等程度的影响。该系列中最好的化合物比维拉帕米、地尔硫䓬、氟桂利嗪和利多氟嗪更有效,但比硝苯地平效力低。以30mg/kg的口服剂量在自发性高血压大鼠(SHR)中评估化合物的抗高血压活性。在测试的55种化合物中,只有9种产生了统计学上显著的(p小于0.05)血压降低,降幅超过20%;所有这些化合物在二苯甲基的两个环上都有氟取代基。在30mg/kg剂量下,SHR中最具活性的化合物之一是1-[4-[3-[4-[双(3,4-二氟苯基)甲基]-1-哌啶基]丙氧基]-3-甲氧基苯基]乙酮(63),它使血压降低了35%,活性与硝苯地平相似。然而,在较低剂量下,4-[双(4-氟苯基)甲基]-1-[3-(4-氯苯氧基)丙基]哌啶(93)是最有效的抗高血压药物之一,在10mg/kg和3mg/kg口服剂量下分别使血压降低了17%和11%;63在10mg/kg时无活性。